In fact, in 2015, both FDA and EMA approved dinutuximab in combination with GM-CSF, IL-2, and CRA after aHSCT for the treatment of pediatric patients with HR-NB who achieved at least partial response (PR) with prior first-line therapy. This evidence concerns the gene IL2 and neuroblastoma.